Table 2.
Efficacy and effectiveness of the recombinant zoster vaccine (RZV) in adults.
| Efficacy | Effectiveness 1 | |||
|---|---|---|---|---|
| Author, Year | Lal ZOE-50 (2015) |
Cunningham ZOE-70 (2016) |
Izurieta (2021) |
Sun (2021) |
| Age, years | ≥50 | ≥70 | ≥65 | ≥50 |
| Efficacy against HZ, % (95% CI) | 97.2 (93.7–99.0) | 89.8 (84.2–93.7) | 70.1(68.6–71.5) | 68.3 (64.4–71.7) |
| 50–59 yrs | 96.6 (89.6–99.3) | ----- | ----- | 85.6 (53.3–95.6) |
| 60–69 yrs | 97.4 (90.1–99.7) | ----- | 70.6 (68.9–72.1) 2 | 87.7 (82.5–91.4) |
| 70–79 yrs | 97.9 (87.9–100) | 90.0 (83.5–94.4) | 70.6 (68.9–72.1) 2 | 86.5 (83.9–88.6) |
| ≥80 | ----- | 89.1 (74.6–96.2) | 68.5 (65.1–71.6) | 80.3 (75.1–84.3) |
| Efficacy against PHN, % (95% CI) | ||||
| 50–59 yrs | 91.2 (75.9–97.7) 1 | 91.2 (75.9–97.7) 1 | 76.0 (68.4–81.8) | ----- |
| 60–69 yrs | ----- | ----- | ----- | ----- |
| ≥70 yrs | 88.8 (68.7–97.1) | 88.8 (68.7–97.1) | ----- | ----- |
| Efficacy against HZO, % (95% CI) | ----- | ----- | 66.8 (60.7–72.0) | ----- |
1 Pooled vaccine effectiveness for PHN from two clinical trials. 2 Vaccine effectiveness estimates for individuals aged 65 to 79 years. Abbreviations: HZ—herpes zoster; PHN—post-herpetic neuralgia; HZO—herpes zoster ophthalmitis; CI—confidence interval.